

CONTACT: Brian Bennett
(501)225-9733



(For Immediate Release)

i3 TO ANNOUNCE EXPANSION IN JAPAN
More Than 70 Industry Executives Expected to Attend July 1 Strategic Discussion Event

Tokyo, Japan, June 25, 2009— Pharmaceutical services company i3 will announce the expansion of its operations in Japan at a meeting of leading pharmaceutical company executives in Tokyo on July 1. i3 is leveraging the extensive resources of its parent company, UnitedHealth Group (NYSE: UNH), to better serve its Japanese customers, as well as global customers with needs in Japan. UnitedHealth Group is a *Fortune* 25, \$80 billion, global health and well-being leader, employing more than 75 thousand people around the world.

With its increased commitment to opportunities in Japan, i3 has created a new, separate operating region, and is opening a new office in Tokyo.

On July 1, over 70 leading industry executives are expected to attend an event to learn more about i3's plans for growth in Japan. i3's CEO, Glenn Bilawsky, and President and CEO of UnitedHealth Group, Stephen Hemsley, will lead a discussion of i3's capabilities and strategy. The event will take place Wednesday, July 1, at Hotel Okura. A reception will follow.

“With deeper financial and human capital investments in Japan, we will be able to better serve Japanese companies directly, and will enhance our offer to international pharmaceutical companies with needs in Japan,” said Mr. Bilawsky. “By cultivating our relationships with Japanese companies through their U.S. and European affiliates, we have already become a significant provider of services to the Japanese pharmaceutical industry. Now, we will have an expanded operational presence in Japan, one of the most important pharmaceutical markets in the world.”

i3's expansion in Japan builds on its experience with customers in the Asia Pacific region, gained with its 2006 acquisition of Singapore-based Pacific Pharma Partners PTE, LT. This acquisition enriched i3's ability to meet growing customer demand for clinical research services in the Far East. In addition, i3 has developed long-standing relationships through many projects with the U.S. and European affiliates of Japanese pharmaceutical companies, and has been working on the ground, building a solid business foundation, while conducting several global studies in Japan.

The new i3 office is located at Nichiga Building, 5th Floor, 1-4-7 Shiba, Minato-ku, Tokyo 105-0014, telephone +81 3 4578 7900.

Individuals interested in attending or obtaining more information about the event should contact Kumpei Kobayashi at +81 3 5418 6478.

-more-

i3 Japan/2

About i3

i3, a global UnitedHealth Group company, provides integrated scientific strategies and solutions throughout the pharmaceutical product lifecycle. It is composed of i3 Research, a therapeutically specialized contract research organization; i3 Drug Safety, engaged in pharmacovigilance and epidemiology; i3 Pharma Informatics, a data, science and technology provider of market analytics; i3 Statprobe, a leader in comprehensive data services; i3 Pharma Resourcing, a world-class staffing partner; and i3 Innovus, delivering the science and solutions to achieve marketplace success. i3 helps companies gain sharper insights that lead to better patient care. For more information, visit www.i3global.com.

About UnitedHealth Group

UnitedHealth Group is a diversified health and well-being company dedicated to making health care work better. Headquartered in Minneapolis, Minn., UnitedHealth Group offers a broad spectrum of products and services through six operating businesses: United Healthcare, Ovation, AmeriChoice, OptumHealth, Ingenix, and Prescription Solutions. Through its family of businesses, UnitedHealth Group serves more than 70 million individuals in the United States.

#